FDA Targets Hidden Aluminum in Hospital Nutrition Drips
Published Date: 7/3/2025
Notice
Summary
The FDA just dropped new draft rules to help drug makers keep aluminum levels safe in small and bulk parenteral nutrition products. If you make or use these products, you’ll need to follow updated labeling and aluminum limits to protect patients. This update replaces last year’s draft and aims to make sure everyone knows exactly how much aluminum is safe and how to show it on labels.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
New Aluminum Calculation Guidance
The FDA's draft guidance tells drug sponsors how to calculate aluminum content so total aluminum exposure from parenteral nutrition (PN) does not exceed an acceptable threshold. This guidance applies to small volume parenteral (SVP) drug products and pharmacy bulk packages (PBPs) used in PN.
Recommended Aluminum Concentration Limits
The draft guidance provides FDA recommendations on aluminum concentration limits for SVPs packaged as single doses and SVPs packaged in pharmacy bulk packages (PBPs). Sponsors should use these recommended limits when assessing their products for parenteral nutrition use.
Labeling Placement for Aluminum Toxicity Info
The draft guidance gives FDA recommendations on where to place information about aluminum toxicity in SVP and large volume parenteral (LVP) Prescribing Information and on container and carton labeling. Sponsors and applicants should follow these recommendations when preparing or updating labeling.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2025-12402, Agency Information Collection Activities: Proposed Collection; Comment Request
CMS wants your thoughts on their plan to collect info from the public and is asking for comments over the next 60 days. This helps make sure the questions they ask aren’t too much work and actually useful. If you’re someone who deals with CMS forms, this is your chance to speak up before any changes happen.
Next: 2025-12408, Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
The FDA just got the green light from the Office of Management and Budget to keep collecting important info from businesses and the public. This means some forms and surveys will continue, helping the FDA keep food and medicine safe without extra costs or delays. If you’re involved with FDA rules, keep an eye out for these approved info requests and their deadlines!